Streptokinase in a COVID-19-positive patient with STEMI in a PPCI centre: A local experience

Nasir Rahman, Ihsan Ullah, Ghufran Adnan

Research output: Contribution to journalArticlepeer-review


Primary percutaneous coronary intervention is the recommended modality of treatment for acute ST-elevation myocardial infarction (STEMI). However, different countries now have different consensus about treatment of patients with STEMI during the COVID-19 pandemic. In this report, we describe a case of SARS-CoV-2-positive patient admitted with pneumonia. During hospital stay in COVID-19 designated special care, the patient developed inferoposterior wall myocardial infarction (MI) without haemodynamic instability and was treated successfully with thrombolytics (streptokinase) without any severe complications. To decrease the risk of in-hospital exposure to COVID-19 infection among the staff, in circumstances where there is no negative-pressure catheterisation laboratory and there is shortage in medical staff, thrombolytics can be used as a modality of treatment in low-risk, haemodynamically stable MI during this pandemic, as recommended by different cardiac societies. However, this needs further studies in order to reach local and international consensus.

Original languageEnglish
Article numbere239068
JournalBMJ Case Reports
Issue number1
Publication statusPublished - 25 Jan 2021


  • cardiovascular medicine
  • ischaemic heart disease


Dive into the research topics of 'Streptokinase in a COVID-19-positive patient with STEMI in a PPCI centre: A local experience'. Together they form a unique fingerprint.

Cite this